• 1
    Dunn AJ, Wang J, Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 1999; 461: 11727.
  • 2
    Rivest S, Lacroix S, Vallieres L, Nadeau S, Zhang J, Laflamme N. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 2000; 223: 2238.
  • 3
    Marcellin P, Lau GKK, Zeuzem S, et al. Comparison of safety, tolerability and quality of life in patients with chronic hepatitis B versus chronic hepatitis C treated with peginterferon alfa-2a (40 KD). Liver Int 2008; 28: 47482.
  • 4
    Kleinman A. Culture and depression. N Engl J Med 2004; 351: 9513.
  • 5
    Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 5539.
  • 6
    Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76: 6008.
  • 7
    Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003; 10: 816.
  • 8
    Kramer L, Bauer E, Funk G, et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002; 37: 34954.
  • 9
    Carta MG, Hardoy MC, Garofano A, et al. Association of chronic hepatitis C with major depressive disorders: irrespective of interferonalpha therapy. Clinical Practice and Epidemiology in Mental Health 2007; 3: 22 [Epub ahead of print].
  • 10
    Lim JK, Cronkite R, Goldstein MK, Cheung RC. The impact of chronic hepatitis C and comorbid psychiatric illnesses on health-related quality of life. J Clin Gastroenterol 2006; 40: 52834.
  • 11
    Fontana RJ, Bieliauskas LA, Lindsay KL, et al. Cognitive function does not worsen during pegylated interferon and Ribavirin retreatment of chronic hepatitis C. Hepatology 2007; 45: 115463.
  • 12
    Ozkan M, Corapçioglu A, Balcioglu I, et al. Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C. Int J Psychiatr Med 2006; 36: 28397.
  • 13
    Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res 2007; 63: 1315.
  • 14
    Staufer K, Ferenci D, Scherzer T, et al. Risk factors for depression during pegInterferoná/ ribavirin therapy in patients with chronic hepatitis C and its impact on virologic response. Psychosomatic Medicine 2007; 69 (Suppl. 65), Abstract 1733, A-88.
  • 15
    Schwarzinger M, Dewedar S, Rekacewicz C, et al. Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt. Hepatology 2004; 40: 143441.
  • 16
    Dalgard O, Egeland A, Skaug K, Vilimas K, Steen T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004; 39: 7480.